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Introduction
IGN311 is a humanized monoclonal IgG1 antibody that
binds to the Lewis Y (LeY) carbohydrate overexpressed on
epithelial cancers. IGN311 potently mediates human
effector functions (ADCC, CDC). The overexpression of
fucosyltransferases in tumor cells also results in glycosyla-
tion of cell surface receptors by LeY. The anti-LeY antibod-
ies IGN311 and its murine parent version ABL 364
therefore might influence the signaling in tumor cells via
inhibition of growth factor receptor functions.
Methods
The present study was designed to provide a proof of con-
cept in vitro: Two human tumor cell lines, A431 and
SKBR3 (vulval carcinoma and breast cancer, respectively)
were propagated under standard cell culture conditions,
rendered quiescent by serum starvation and stimulated by
EGF or heregulin. Cellular effector regulation, growth fac-
tor receptor expression and LeY expression were exam-
ined.
Results
Both ABL 364 and IGN311 blocked the stimulation of
MAP kinase by EGF and heregulin in SKBR3 and A431
cells. The effect was comparable in magnitude with that of
trastuzumab and was apparently non-competitive with
respect to EGF. Finally, IGN311 and ABL 364 inhibited
EGF-stimulated [3H]thymidine incorporation in A431
cells.
Conclusions
Taken together, the observations show that antibodies
against carbohydrate determinants of erbB-familiy mem-
bers are capable of blocking signaling. The clinical profil-
ing of the humanized monoclonal anti Lewis Y antibody
IGN311 has been initiated. Presently a Phase I dose-esca-
lation trial in cancer patients is ongoing.
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